Inari Medical soars on Stryker acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/5/2026
- Dow, S&P 500 close at record on AI-linked earnings, Mideast deal hopes
- Caterpillar stock jumps on strong earnings and revenue beat
- Optical component stocks rally on proposed U.S. ban on Chinese tech
- BofA says this memory stock could double. Here are 5 reasons why
- Merck shares rise on big Q2 earnings beat, adjusted FY outlook
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Opendoor posts Q2 revenue rise as net loss widens year over year
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- Dave & Buster's names CFO Darin Harper as new CEO
- Dow, S&P 500 close at record on AI-linked earnings, Mideast deal hopes
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
BTIG Downgrades Inari Medical Inc. (NARI) to Neutral
January 7, 2025 4:09 PM ESTBTIG analyst Marie Thibault downgraded Inari Medical Inc. (NASDAQ: NARI) from Buy to Neutral.
The analyst comments "We are downgrading NARI shares to Neutral following the announcement on Monday, January 6 that Stryker (SYK, Buy, $394 PT; Analyst: Zimmerman) entered a definitive agreement to... More
Jefferies Downgrades Inari Medical Inc. (NARI) to Hold
January 7, 2025 11:49 AM ESTJefferies analyst Matthew Taylor downgraded Inari Medical Inc. (NASDAQ: NARI) from Buy to Hold with a price target of $80.00 (from $70.00).
The analyst comments "After the market close, SYK announced an agreement to acquire NARI for $80/shr in cash, equating to a fully... More
BofA Securities Reiterates Buy Rating on Stryker (SYK)
January 7, 2025 8:07 AM ESTBofA Securities analyst Travis Steed reiterated a Buy rating and $450.00 price target on Stryker (NYSE: SYK)
The analyst comments "Inside we include our pro forma deal model. We estimate the EPS dilution in year 1 is only slightly dilutive (around 1-3% dilutive) and... More
